Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets

  • Siles-Lucas, Mar
  • Casulli, Adriano
  • Cirilli, Roberto
  • Carmena, David
Human cystic and alveolar echinococcosis are helmintic zoonotic diseases caused by infections with the larval stages of the cestode parasites Echinococcus granulosus and E. multilocularis, respectively. Both diseases are progressive and chronic, and often fatal if left unattended for E. multilocularis. As a treatment approach, chemotherapy against these orphan and neglected diseases has been available for more than 40 years. However, drug options were limited to the benzimidazoles albendazole and mebendazole, the only chemical compounds currently licensed for treatment in humans. To compensate this therapeutic shortfall, new treatment alternatives are urgently needed, including the identification, development, and assessment of novel compound classes and drug targets. Here is presented a thorough overview of the range of compounds that have been tested against E. granulosus and E. multilocularis in recent years, including in vitro and in vivo data on their mode of action, dosage, administration regimen, therapeutic outcomes, and associated clinical symptoms. Drugs covered included albendazole, mebendazole, and other members of the benzimidazole family and their derivatives, including improved formulations and combined therapies with other biocidal agents. Chemically synthetized molecules previously known to be effective against other infectious and non-infectious conditions such as anti-virals, antibiotics, anti-parasites, anti-mycotics, and anti-neoplastics are addressed. In view of their increasing relevance, natural occurring compounds derived from plant and fungal extracts are also discussed. Special attention has been paid to the recent application of genomic science on drug discovery and clinical medicine, particularly through the identification of small inhibitor molecules tackling key metabolic enzymes or signalling pathways.
Repisalud
Publicación Artículo científico (JournalArticle)

Evaluation of the sensitivity and specificity of GST-tagged recombinant antigens 2B2t, Ag5t and DIPOL in ELISA for the diagnosis and follow up of patients with cystic echinococcosis

  • Sánchez-Ovejero, Carlos
  • Akdur, Eylem
  • Manzano-Román, Raúl
  • Hernandez-Gonzalez, Ana
  • González-Sánchez, María
  • Becerro-Recio, David
  • González-Miguel, Javier
  • Akhan, Okan
  • Cretu, Carmen M
  • Vutova, Kamenna
  • Tamarozzi, Francesca
  • Mariconti, Mara
  • Brunetti, Enrico
  • Vola, Ambra
  • Fabiani, Massimo
  • Casulli, Adriano
  • Siles-Lucas, Mar
Cystic echinococcosis (CE) is a neglected zoonotic disease caused by Echinococcus granulosus sensu lato. Diagnosis and monitoring of CE rely primarily on imaging while serology is used as a confirmatory test. However, imaging is not always conclusive and currently available serological assays have suboptimal sensitivity and specificity, lack standardization, and are not useful for patients´ follow-up. Seroassays for CE are usually based on hydatid fluid (HF), a complex, variable antigenic mixture, and cross-reactivity exists especially with alveolar echinococcosis. Recombinant proteins based on immunogenic antigens most abundant in HF, such as AgB1, AgB2 and Ag5, have been used to overcome these limitations. None of them so far showed potential to replace HF; however, their performance have been largely tested on a limited number of samples, and comparison of different antigens using the same cohort has been rarely performed. The combination of several immunogenic epitopes in a single recombinant protein could enhance test sensitivity. For the diagnosis and follow-up of patients with CE, we compared the performance of the crude HF, previously described recombinant 2B2t antigen, and GST-tagged version of 2B2t, and novel designed recombinants (GST-Ag5t and the GST-DIPOL chimera containing AgB1, AgBB2 and Ag5 epitopes) by IgG-ELISA format. Samples belong to a retrospective cohort of 253 well-characterized patients with CE, previously described for the evaluation of the 2B2t antigen, 92 patients with alveolar echinococcosis, and 82 healthy donors. The reference standard for CE diagnosis was the presence of a CE lesion as diagnosed by ultrasonography. The highest sensitivity was obtained with HF [86.7%, 95% confidence interval (CI): 81.2-91.0], followed by GST-2B2t (70.0%, 95% CI: 63.1-76.2), 2B2t (65.5%, 95% CI: 58.5-72.0), GST-Ag5t (64.5%, 95% CI: 57.5-71.1) and GST-DIPOL (63.1%, 95% CI: 56.0-69.7). The GST-2B2t had the best specificity (95.8%, 95% CI: 88.3-99.1) and the lowest cross-reactivity (38.7%, 95% CI: 27.6-50.6). Good response to treatment also correlated to negative test results in the GST-2B2t ELISA. While none of the tested recombinant antigen appears suitable to replace HF for the diagnosis of CE, GST-2B2t should be further explored as a confirmation test, based on its high specificity and low cross-reactivity, and for the follow-up after treatment in those patients with positive serology for this antigen.
Repisalud
Publicación Artículo científico (JournalArticle)

Evaluation of the recombinant antigens B2t and 2B2t, compared with hydatid fluid, in IgG-ELISA and immunostrips for the diagnosis and follow up of CE patients

  • Hernandez-Gonzalez, Ana
  • Sánchez-Ovejero, Carlos
  • Manzano-Román, Raúl
  • González Sánchez, María
  • Delgado, José Manuel
  • Pardo-García, Teresa
  • Soriano-Gálvez, Francisco
  • Akhan, Okan
  • Cretu, Carmen M
  • Vutova, Kamenna
  • Tamarozzi, Francesca
  • Mariconti, Mara
  • Brunetti, Enrico
  • Vola, Ambra
  • Fabiani, Massimo
  • Casulli, Adriano
  • Siles-Lucas, Mar
Cystic echinococcosis (CE) is one of the most widespread helminthic zoonoses and is caused by the tapeworm Echinococcus granulosus complex. CE diagnosis and monitoring primarily rely on imaging techniques, complemented by serology. This is usually approached by the detection of IgG antibodies against hydatid fluid (HF), but the use of this heterogeneous antigenic mixture results in a variable percentage of false positive and negative results, and has shown to be useless for follow-up due to the long persistence of anti-HF antibodies in cured patients. To improve test performances and standardization, a number of recombinant antigens mainly derived from HF have been described, among them the B2t and 2B2t antigens. The performance of these antigens in the diagnosis and follow up of patients with CE has been so far evaluated on a limited number of samples. Here, we evaluated the performances of tests based on B2t and 2B2t recombinant antigens compared to HF in IgG-ELISA and immunochromatography (IC) for the diagnosis and follow-up of patients with CE in a retrospective cohort study. A total of 721 serum samples were collected: 587 from 253 patients with CE diagnosed by ultrasonography (US), 42 from patients with alveolar echinococcosis and 92 from healthy donors from Salamanca (Spain). The highest overall sensitivity was obtained with HF in ELISA (85.5%), followed by IC containing HF and 2B2t-HF (83.0% and 78.2%, respectively). The lowest sensitivity was obtained with B2t and 2B2t in ELISA (51.8%). The highest specificity was obtained with IC containing 2B2t-HF (100%), and the lowest with HF-ELISA (78.0%). The lowest cross-reactivity with sera from patients with alveolar echinococcosis was detected with the recombinant antigens in ELISA (9.5% - 16.7%) and the highest with the HF-IC (64.3%). The results of B2t and 2B2t-ELISA were influenced by cyst stage, as classified by US according to the WHO-Informal Working Group on Echinococcosis (WHO-IWGE), with low sensitivity for inactive (CE4 and CE5) cysts, and by the drug treatment, with higher sensitivity in patients after drug treatment compared with patients not subjected to drug treatment. The two recombinant antigens in ELISA provided promising results for monitoring patients in follow-up, although their use is limited to patients with positive serology against them at the beginning of the follow-up. Potential biological reasons behind the low sensitivity of the recombinant antigens and possible strategies to enhance the performance of CE serology are discussed.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Serological Diagnosis and Follow-Up of Human Cystic Echinococcosis: A New Hope for the Future?

  • Manzano Román, Raúl
  • Sánchez Ovejero, Carlos
  • Hernández González, Ana
  • Casulli, Adriano
  • Siles Lucas, Mar
10 páginas, 2 tablas. --, Cystic echinococcosis (CE) is an important helminthic zoonotic disease caused by the Echinococcus granulosus complex. In humans, CE is a chronic disease driven by the growth of echinococcal cysts in different organs. Prognosis of this disease depends onmultiple factors, including location, number, size, and stage of the cysts, making CE a disease of complex management. CE is usually asymptomatic for years and attracts limited attention from funding organizations and health authorities. For this reason, only experts’ recommendations are available but no evidence-based conclusions have been drawn for CE clinical management. One of those pitfalls refers to the lack of evidence to support the use of serological tools for the diagnosis and follow-up of CE patients. In this respect, crude antigens are used to detect specific antibodies in patients, giving rise to false positive results.The advent of molecular techniques allowing the production of recombinant proteins has provided a number of candidate antigens that could overcome the problems associated with the use of crude parasite extracts in the serological assays. In this review, we present the last advances in this field, proposing the use of serology to support cyst stage-specific diagnosis and follow-up., The research that will lead to these results has received funding from the European Community’s Seventh Framework Programmeunder theGrant agreement 602051 (Project HERACLES: Human cystic Echinococcosis ReseArch in CentraL and Eastern Societies; http://www.Heracles-fp7.eu/)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sensing parasites: proteomic and advanced bio-detection alternatives

  • Sánchez Ovejero, Carlos
  • Benito-López, Fernando
  • Díez, Paula
  • Casulli, Adriano
  • Siles Lucas, Mar
  • Fuentes, Manuel
  • Manzano Román, Raúl
38 páginas, 4 tablas. -- The definitive version is available at http://www.elsevier.com, Parasitic diseases have a great impact in human and animal health. The gold standard for the diagnosis of the majority of parasitic infections is still conventional microscopy, which presents important limitations in terms of sensitivity and specificity and commonly requires highly trained technicians. More accurate molecular-based diagnostic tools are needed for the implementation of early detection, effective treatments and massive screenings with high-throughput capacities. In this respect, sensitive and affordable devices could greatly impact on sustainable control programmes which exist against parasitic diseases, especially in low income settings. Proteomics and nanotechnology approaches are valuable tools for sensing pathogens and host alteration signatures within microfluidic detection platforms. These new devices might provide novel solutions to fight parasitic diseases. Newly described specific parasite derived products with immune-modulatory properties have been postulated as the best candidates for the early and accurate detection of parasitic infections as well as for the blockage of parasite development. This review provides the most recent methodological and technological advances with great potential for biosensing parasites in their hosts, showing the newest opportunities offered by modern “-omics” and platforms for parasite detection and control, This research was funded by HERACLES project (http://www.heracles-fp7.eu/) under the Seventh Framework Programme of the European Commission. FBL acknowledges the support of the Ramón y Cajal programme (Ministerio de Economía y Competitividad). We also gratefully acknowledge financial support from the Carlos III Health Institute of Spain (ISCIII, FIS PI14/01538 and FIS PI12/00624), Fondos FEDER (EU) and Junta Castilla-León BIO/SA07/15. The Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by grant PT13/0001. P.D. is supported by a JCYLEDU/346/2013 Ph.D. scholarship., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The first meeting of the European Register of Cystic Echinococcosis (ERCE)

  • Rossi, Patrizia
  • Tamarozzi, Francesca
  • Siles Lucas, Mar
  • Siles Lucas, Mar
  • Zammarchi, L.
6 páginas, 3 figuras, 1 tabla, Cystic echinococcosis (CE) is a zoonotic parasitic disease endemic in southern and eastern European countries. The true prevalence of CE is difficult to estimate due to the high proportion of asymptomatic carriers who never seek medical attention and to the underreporting of diagnosed cases, factors which contribute to its neglected status. In an attempt to improve this situation, the European Register of Cystic Echinococcosis (ERCE), was launched in October 2014 in the context of the HERACLES project. ERCE is a prospective, observational, multicentre register of patients with probable or confirmed CE. The first ERCE meeting was held in November 2015 at the Italian National Institute of Health (Istituto Superiore di Sanita, ISS) in Rome, to bring together CE experts currently involved in the Register activities, to share and discuss experiences, and future developments. Although the Register is still in its infancy, data collected at the time of writing this report, had outnumbered the total of national cases reported by the European endemic countries and published by the European Centre for Disease Prevention and Control in 2015. This confirms the need for an improved reporting system of CE at the European level. The collection of standardized clinical data and samples is expected to support a more rational, stage-specific approach to clinical management, and to help public authorities harmonize reporting of CE. A better understanding of CE burden in Europe will encourage the planning and implementation of public health policies toward its control., This research received funding from the European Community’s Seventh Framework Programme under the grant agreement 602051 (Project HERACLES: Human cystic Echinococcosis ReseArch in CentraL and Eastern Societies; http:// www.heracles-fp7.eu/)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Potential Risk Factors Associated with Human Cystic Echinococcosis: Systematic Review and Meta-analysis

  • Possenti, Alessia
  • Manzano Román, Raúl
  • Sánchez Ovejero, Carlos
  • Boufana, Belgees
  • La Torre, Giuseppe
  • Siles Lucas, Mar
  • Casulli, Adriano
15 páginas, 2 figuras, 2 tablas, Background Scientific literature on cystic echinococcosis (CE) reporting data on risk factors is limited and to the best of our knowledge, no global evaluation of human CE risk factors has to date been performed. This systematic review (SR) summarizes available data on statistically relevant potential risk factors (PRFs) associated with human CE., Methodology/Principal Findings Database searches identified 1,367 papers, of which thirty-seven were eligible for inclusion. Of these, eight and twenty-nine were case-control and cross-sectional studies, respectively. Among the eligible papers, twenty-one were included in the meta-analyses. Pooled odds ratio (OR) were used as a measure of effect and separately analysed for the two study designs. PRFs derived from case-control studies that were significantly associated with higher odds of outcome were ªdog free to roamº (OR 5.23; 95% CI 2.45±11.14), ªfeeding dogs with visceraº (OR 4.69; 95% CI 3.02±7.29), ªslaughter at homeº (OR 4.67; 95% CI 2.02±10.78) or at ªslaughterhousesº (OR 2.7; 95% CI 1.15±6.3), ªdog ownershipº (OR 3.54; 95% CI 1.27±9.85), ªliving in rural areasº (OR 1.83; 95% CI 1.16±2.9) and ªlow incomeº (OR 1.68; 95% CI 1.02±2.76). Statistically significant PRFs from cross-sectional studies with higher odds of outcome were ªage >16 yearsº (OR 6.08; 95% CI 4.05±9.13), ªliving in rural areasº (OR 2.26; 95% CI 1.41±3.61), ªbeing femaleº (OR 1.38; 95% CI 1.06± 1.8) and ªdog ownershipº (OR 1.37; 95% CI 1.01±1.86). Conclusions/Significance Living in endemic rural areas, in which free roaming dogs have access to offal and being a dog-owner, seem to be among the most significant PRFs for acquiring this parasiticinfection. Results of data analysed here may contribute to our understanding of the PRFs for CE and may potentially be useful in planning community interventions aimed at controlling CE in endemic areas., Conclusions/Significance Living in endemic rural areas, in which free roaming dogs have access to offal and being a dog-owner, seem to be among the most significant PRFs for acquiring this parasiticinfection. Results of data analysed here may contribute to our understanding of the PRFs for CE and may potentially be useful in planning community interventions aimed at controlling CE in endemic areas., This research received funding from the European Community's Seventh Framework Programme under the grant agreement 602051 (Project HERACLES: Human cystic Echinococcosis ReseArch in CentraL and Eastern Societies; http://www.heracles-fp7.eu/)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets

  • Siles Lucas, Mar
  • Casulli, Adriano
  • Cirilli, Roberto
  • Carmena, David
48 páginas, 1 figura, 4 tablas, Human cystic and alveolar echinococcosis are helmintic zoonotic diseases caused by infections with the larval stages of the cestode parasites Echinococcus granulosus and E. multilocularis, respectively. Both diseases are progressive and chronic, and often fatal if left unattended for E. multilocularis. As a treatment approach, chemotherapy against these orphan and neglected diseases has been available for more than 40 years. However, drug options were limited to the benzimidazoles albendazole and mebendazole, the only chemical compounds currently licensed for treatment in humans. To compensate this therapeutic shortfall, new treatment alternatives are urgently needed, including the identification, development, and assessment of novel compound classes and drug targets. Here is presented a thorough overview of the range of compounds that have been tested against E. granulosus and E. multilocularis in recent years, including in vitro and in vivo data on their mode of action, dosage, administration regimen, therapeutic outcomes, and associated clinical symptoms. Drugs covered included albendazole, mebendazole, and other members of the benzimidazole family and their derivatives, including improved formulations and combined therapies with other biocidal agents. Chemically synthetized molecules previously known to be effective against other infectious and non-infectious conditions such as anti-virals, antibiotics, anti-parasites, anti-mycotics, and anti-neoplastics are addressed. In view of their increasing relevance, natural occurring compounds derived from plant and fungal extracts are also discussed. Special attention has been paid to the recent application of genomic science on drug discovery and clinical medicine, particularly through the identification of small inhibitor molecules tackling key metabolic enzymes or signalling pathways., This work was supported by the European Union Seventh Framework Programme (FP7) under the project HERACLES (http://www.Heracles-fp7.eu/), grant agreement No. 602051., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evaluation of the recombinant antigens B2t and 2B2t, compared with hydatid fluid, in IgGELISA and immunostrips for the diagnosis and follow up of CE patients

  • Hernández González, Ana
  • Sánchez Ovejero, Carlos
  • Manzano Román, Raúl
  • González-Sánchez, María
  • Delgado, José Manuel
  • Pardo García, Teresa
  • Soriano-Gálvez, Francisco
  • Akhan, Okan
  • Cretu, Carmen Michaela
  • Vutova, Kamenna
  • Tamarozzi, Francesca
  • Mariconti, Mara
  • Brunetti, Enrico
  • Vola, Ambra
  • Fabiani, Massimo
  • Casulli, Adriano
  • Siles Lucas, Mar
21 páginas, 5 figuras y 7 tablas., Cystic echinococcosis (CE) is one of the most widespread helminthic zoonoses and is caused by the tapeworm Echinococcus granulosus complex. CE diagnosis and monitoring primarily rely on imaging techniques, complemented by serology. This is usually approached by the detection of IgG antibodies against hydatid fluid (HF), but the use of this heterogeneous antigenic mixture results in a variable percentage of false positive and negative results, and has shown to be useless for follow-up due to the long persistence of anti-HF antibodies in cured patients. To improve test performances and standardization, a number of recombinant antigens mainly derived from HF have been described, among them the B2t and 2B2t antigens. The performance of these antigens in the diagnosis and follow up of patients with CE has been so far evaluated on a limited number of samples. Here, we evaluated the performances of tests based on B2t and 2B2t recombinant antigens compared to HF in IgG-ELISA and immunochromatography (IC) for the diagnosis and follow-up of patients with CE in a retrospective cohort study. A total of 721 serum samples were collected: 587 from 253 patients with CE diagnosed by ultrasonography (US), 42 from patients with alveolar echinococcosis and 92 from healthy donors from Salamanca (Spain). The highest overall sensitivity was obtained with HF in ELISA (85.5%), followed by IC containing HF and 2B2t-HF (83.0% and 78.2%, respectively). The lowest sensitivity was obtained with B2t and 2B2t in ELISA (51.8%). The highest specificity was obtained with IC containing 2B2t-HF (100%), and the lowest with HF-ELISA (78.0%). The lowest cross-reactivity with sera from patients with alveolar echinococcosis was detected with the recombinant antigens in ELISA (9.5% - 16.7%) and the highest with the HF-IC (64.3%). The results of B2t and 2B2t-ELISA were influenced by cyst stage, as classified by US according to the WHO-Informal Working Group on Echinococcosis (WHO-IWGE), with low sensitivity for inactive (CE4 and CE5) cysts, and by the drug treatment, with higher sensitivity in patients after drug treatment compared with patients not subjected to drug treatment. The two recombinant antigens in ELISA provided promising results for monitoring patients in follow-up, although their use is limited to patients with positive serology against them at the beginning of the followup. Potential biological reasons behind the low sensitivity of the recombinant antigens and possible strategies to enhance the performance of CE serology are discussed., This research received funding from the European Community's Seventh Framework Programme under the grant agreement 602051 (Project HERACLES: Human cystic Echinococcosis ReseArch in CentraL and Eastern Societies; http:// www.heracles-fp7.eu/). The funding body had no involvement in the conception, preparation and writing of the manuscript, in the viewpoints expressed, nor in the decision to submit this article., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epidemiological factors associated with human cystic echinococcosis: a semi-structured questionnaire from a large population-based ultrasound cross-sectional study in eastern Europe and Turkey

  • Tamarozzi, Francesca
  • Akhan, Okan
  • Cretu, Carmen Michaela
  • Vutova, Kamenna
  • Fabiani, Massimo
  • Orsten, Serra
  • Pezzotti, Patrizio
  • Popa, Gabriela L.
  • Velev, Valeri
  • Siles Lucas, Mar
  • Brunetti, Enrico
  • Casulli, Adriano
[Background] Cystic echinococcosis (CE) is a neglected parasitic zoonosis prioritized by the WHO for control. Several studies have investigated potential risk factors for CE through questionnaires, mostly carried out on small samples, providing contrasting results. We present the analysis of risk factor questionnaires administered to participants to a large CE prevalence study conducted in Bulgaria, Romania and Turkey., [Methods] A semi-structured questionnaire was administered to 24,687 people from rural Bulgaria, Romania and Turkey. CE cases were defined as individuals with abdominal CE cysts detected by ultrasound. Variables associated with CE at P < 0.20 in bivariate analysis were included into a multivariable logistic model, with a random effect to account for clustering at village level. Adjusted odds ratios (AOR) with 95% CI were used to describe the strength of associations. Data were weighted to reflect the relative distribution of the rural population in the study area by country, age group and sex., [Results] Valid records from 22,027 people were analyzed. According to the main occupation in the past 20 years, “housewife” (AOR: 3.11; 95% CI: 1.51–6.41) and “retired” (AOR: 2.88; 95% CI: 1.09–7.65) showed significantly higher odds of being infected compared to non-agricultural workers. “Having relatives with CE” (AOR: 4.18; 95% CI: 1.77–9.88) was also associated with higher odds of infection. Interestingly, dog-related and food/water-related factors were not associated with infection., [Conclusions] Our results point toward infection being acquired in a “domestic” rural environment and support the view that CE should be considered more a “soil-transmitted” than a “food-borne” infection. This result helps delineating the dynamics of infection transmission and has practical implications in the design of specific studies to shed light on actual sources of infection and inform control campaigns., The research leading to these results received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under the project HERACLES, grant agreement no. 602051., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The European Register of Cystic Echinococcosis, ERCE: state-of-the-art five years after its launch, Parasites & vectors, 13: 236

  • Rossi, Patrizia
  • Tamarozzi, Francesca
  • Galati, Fabio
  • Akhan, Okan
  • Cretu, Carmen Michaela
  • Vutova, Kamenna
  • Siles Lucas, Mar
  • Brunetti, Enrico
  • Casulli, Adriano
  • ERCE network
10 páginas, 3 tablas, 4 figuras, Background: The real burden of human cystic echinococcosis (CE) remains elusive, due to the peculiar characteristics of the disease and the heterogeneous and incomplete data recording of clinical cases. Furthermore, official notification systems do not collect pivotal clinical information, which would allow the comparison of different treatment outcomes, and thus circumvent the difficulty of implementing clinical trials for CE. The Italian Register of CE (RIEC) was launched in 2012 and expanded in 2014 into the European Register of CE (ERCE). The primary aim of the ERCE was to highlight the magnitude of CE underreporting, through the recording of cases that were not captured by official records. We present an overview of data collated in the ERCE and discuss its future, five years after its inception. Methods: The ERCE database was explored on March 31st 2019; data concerning participating centres and registered cases were descriptively analysed. Results: Forty-four centres from 15 countries (7 non-European) were affiliated to the ERCE. Thirty-four centres (77%) registered at least one patient; of these, 18 (53%) recorded at least one visit within the past 18 months. A total of 2097 patients were registered, 19.9% of whom were immigrants. Cyst characteristics were reported for at least one cyst at least in one visit in 1643 (78.3%) patients, and cyst staging was used by 27 centres. In total, 3386 cysts were recorded at first registration; mostly located in the liver (75.5%). Data concerning clinical management could be analysed for 920 “cyst stage-location-management” observations, showing great heterogeneity in the implementation of the stage-specific management approach recommended by the WHO. Conclusions: The ERCE achieved its goal in showing that CE is a relevant but neglected public health problem in Europe and beyond, since a proportion of patients reaching medical attention are not captured by official notification systems. The ERCE may provide a valuable starting platform to complement hospital-derived data, to obtain a better picture of the epidemiology of clinical CE, and to collect clinical data for the issue of evidence-based recommendations. The ERCE will be expanded into the International Register of CE (IRCE) and restructured aiming to overcome its current criticalities and fulfil these aims, RIEC development received funding through the Research Project IZSSA07/10RC to Dr. Giovanna Masala (Sardinian Experimental Zooprophylactic Institute, Sassari, Italy), subcontracted to Enrico Brunetti, University of Pavia, Italy. The amendment of RIEC and development of the ERCE was funded through the European Commission, under the Seventh Framework Programme (FP7, Theme Health.2013.2.3.4-1, grant agreement. no. 602051, Project HERACLES: Human Cystic Echinococcosis ReseArch in Central and Eastern Societies; http://www.herac les-fp7.eu/) to Adriano Casulli, Istituto Superiore di Sanità, Rome, Italy. ERCE activities are currently supported by EULAC Health (http://eulac healt h.eu/) and the Italian Ministry of Health - PERITAS project (molecular ePidemiological studiEs on pathways of tRansmIssion and long lasTing cApacity building to prevent cyStic echinococcosis infection) to Adriano Casulli, Istituto Superiore di Sanità, Rome, Italy., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Diagnostic performances of commercial ELISA, indirect hemagglutination, and western blot in differentiation of hepatic echinococcal and non-echinococcal lesions: A retrospective analysis of data from a single referral centre

  • Vola, Ambra
  • Manciulli, Tommaso
  • De Silvestri, Annalisa
  • Lissandrin, Raffaella
  • Mariconti, Mara
  • Siles Lucas, Mar
  • Brunetti, Enrico
  • Tamarozzi, Francesca
5 páginas, 3 tablas, The diagnosis of cystic echinococcosis (CE) is based on imaging. Serology supports imaging in suspected cases, but no consensus exists on the algorithm to apply when imaging is inconclusive. We performed a retrospective analysis of serology results of patients with untreated hepatic CE and non-CE lesions, seen from 2005 to 017, to evaluate their accuracy in the differential diagnosis of hepatic CE. Serology results of three seroassays for echinococcosis (ELISA RIDASCREEN, indirect hemagglutination (IHA) Cellognost, and Western blot LDBIO) and clinical characteristics of eligible patients were retrieved. Patients were grouped as having active or inactive CE and liquid or solid non-CE lesions. Sensitivity, specificity, and diagnostic accuracy were compared between scenarios encompassing different test combinations. Eligible patients included 104 patients with CE and 257 with non-CE lesions. Sensitivity and diagnostic accuracy ofWestern blot (WB)were significantly higher than those of the following: 1) IHA or ELISA alone, 2) IHA+ELISA interpreted as positive if both or either tests positive, and 3) IHA+ELISA confirmed by WB if discordant. The best performances were obtained when WB was applied on discordant or concordant negative IHA+ELISA. Analyses performed within “active CE (n = 52) versus liquid non-CE (n = 245)” and “inactive CE (n = 52) versus solid non-CE (n = 12)” groups showed similar results. Specificity was high for all tests (0.99–1.00) and did not differ between test combination scenarios. WB may be the best test to apply in a one-test approach. Two first-level tests confirmed by WB seem to provide the best diagnostic accuracy. Further studies should be performed in different settings, especially where lower test specificity is likely., This work was funded by the European Union Seventh Framework Program (FP7/2007–2013) under the project HERACLES, grant agreement no. 602051–to E. B., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evaluation of the sensitivity and specificity of GST-tagged recombinant antigens 2B2t, Ag5t and DIPOL in ELISA for the diagnosis and follow up of patients with cystic echinococcosis

  • Sánchez Ovejero, Carlos
  • Akdur, Eylem
  • Manzano Román, Raúl
  • Hernández González, Ana
  • González-Sánchez, María
  • Becerro Recio, David
  • González Miguel, Javier
  • Akhan, Okan
  • Cretu, Carmen Michaela
  • Vutova, Kamenna
  • Tamarozzi, Francesca
  • Mariconti, Mara
  • Brunetti, Enrico
  • Vola, Ambra
  • Fabiani, Massimo
  • Casulli, Adriano
  • Siles Lucas, Mar
20 páginas, 4 figuras y 5 tablas, Cystic echinococcosis (CE) is a neglected zoonotic disease caused by Echinococcus granulosus sensu lato. Diagnosis and monitoring of CE rely primarily on imaging while serology is used as a confirmatory test. However, imaging is not always conclusive and currently available serological assays have suboptimal sensitivity and specificity, lack standardization, and are not useful for patients´ follow-up. Seroassays for CE are usually based on hydatid fluid (HF), a complex, variable antigenic mixture, and cross-reactivity exists especially with alveolar echinococcosis. Recombinant proteins based on immunogenic antigens most abundant in HF, such as AgB1, AgB2 and Ag5, have been used to overcome these limitations. None of them so far showed potential to replace HF; however, their performance have been largely tested on a limited number of samples, and comparison of different antigens using the same cohort has been rarely performed. The combination of several immunogenic epitopes in a single recombinant protein could enhance test sensitivity. For the diagnosis and follow-up of patients with CE, we compared the performance of the crude HF, previously described recombinant 2B2t antigen, and GST-tagged version of 2B2t, and novel designed recombinants (GST-Ag5t and the GST-DIPOL chimera containing AgB1, AgBB2 and Ag5 epitopes) by IgG-ELISA format. Samples belong to a retrospective cohort of 253 well-characterized patients with CE, previously described for the evaluation of the 2B2t antigen, 92 patients with alveolar echinococcosis, and 82 healthy donors. The reference standard for CE diagnosis was the presence of a CE lesion as diagnosed by ultrasonography. The highest sensitivity was obtained with HF [86.7%, 95% confidence interval (CI): 81.2–91.0], followed by GST-2B2t (70.0%, 95% CI: 63.1–76.2), 2B2t (65.5%, 95% CI: 58.5–72.0), GST-Ag5t (64.5%, 95% CI: 57.5–71.1) and GST-DIPOL (63.1%, 95% CI: 56.0–69.7). The GST-2B2t had the best specificity (95.8%, 95% CI: 88.3–99.1) and the lowest cross-reactivity (38.7%, 95% CI: 27.6–50.6). Good response to treatment also correlated to negative test results in the GST-2B2t ELISA. While none of the tested recombinant antigen appears suitable to replace HF for the diagnosis of CE, GST-2B2t should be further explored as a confirmation test, based on its high specificity and low cross-reactivity, and for the follow-up after treatment in those patients with positive serology for this antigen., This work was supported by the European Commission Seventh Framework Programme (FP7) under the HERACLES project (grant agreement n 602051; http://www.heraclesfp7.eu/). RMR, OA, CMC, KV, FT, EB, AC AND MSL were supported by the European Commission Seventh Framework Programme (FP7). JGM is supported by the JIN project “ULYSSES” (RTI2018-093463-J-100) (MCIU/AEI/FEDER, UE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Achievements of the HERACLES Project on Cystic Echinococcosis

  • Casulli, Adriano
  • Siles Lucas, Mar
  • Michaela Cretu, Carmen
  • Vutova, Kamenna
  • Akhan, Okan
  • Vural, Gulay
  • Cortés Ruiz, Arantxa
  • Brunetti, Enrico
  • Tamarozzi, Francesca
4 páginas, 2 figuras y 1 cuadro, The FP7 project ’Human Cystic Echinococcosis ReseArch in CentraL and Eastern Societies’ (HERACLES), developed between 2013 and 2018 by nine partners in five countries, is one of the largest projects on cystic echinococcosis. Here we present the core HERACLES achievements, which should help to foster the translation of scientific investigations on health policies., This work was supported by the European Commission Seventh Framework Programme (FP7) under the HERACLES project (grant agreement number 602051)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Efficacy of novel albendazole salt formulations against secondary cystic echinococcosis in experimentally infected mice

  • Vural, Gulay
  • Yardimci, M.
  • Kocak, M.
  • Yasar, T.Ö.
  • Kurt, A.
  • Harem, I.S.
  • Carradori, S.
  • Sciamanna, I.
  • Siles Lucas, Mar
  • Fabiani, Massimo
  • Hemphill, A.
  • Lundström-Stadelmann, B.
  • Cirilli, R.
  • Casulli, Adriano
8 páginas, 5 figuras, 1 tabla, In this study, we evaluated the efficacy, expressed as a mean weight decrease of the whole echinococcal cyst mass, of novel benzimidazole salt formulations in a murine Echinococcus granulosus infection model. BALB/c mice were intraperitoneally infected with protoscoleces of E. granulosus (genotype G1). At 9 months post-infection, treatment with albendazole (ABZ), ricobendazole (RBZ) salt formulations, and RBZ enantiomer salts (R)-(+)-RBZ-Na and (S)-(−)-RBZ-Na formulations were initiated. Drugs were orally applied by gavage at 10 mg kg−1 body weight per day during 30 days. Experimental treatments with benzimidazole sodium salts resulted in a significant reduction of the weight of cysts compared to conventional ABZ treatment, except for the (S)-(−)-RBZ-Na enantiomer formulation. Scanning electron microscopy and histological inspection revealed that treatments impacted not only the structural integrity of the parasite tissue in the germinal layer, but also induced alterations in the laminated layer. Overall, these results demonstrate the improved efficacy of benzimidazole salt formulations compared to conventional ABZ treatment in experimental murine cystic echinococcosis., The research leading to these results received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under the project HERACLES (http://www.heracles-fp7.eu/), grant agreement no. 602051. The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Comparison of the multi-epitope recombinant antigen DIPOL and hydatid fluid for the diagnosis of patients with cystic echinococcosis

  • Ozturk, Eylem Akdur
  • Manzano Román, Raúl
  • Sánchez Ovejero, Carlos
  • Caner, Ayse
  • Angın, Mesude
  • Gunduz, Cumhur
  • Karaman, Ülkü
  • Altintas, Nuray
  • Bozkaya, Halil
  • Unalp, Omer
  • Dokumcu, Zafer
  • Divarci, Emre
  • Casulli, Adriano
  • Altintas, Nazmiye
  • Siles Lucas, Mar
  • Unver, Aysegul
16 páginas. -- The final version is available at http://www.elsevier.com, The use of serological tests containing multiple immunodominant antigens rather than single antigens have the potential to improve the diagnostic performance in Cystic Echinococcoses (CE) as a complement tool to clear the inconclusive imaging data. Here, we comparatively evaluated the diagnostic value of Hydatid Fluid (HF) and the recently described recombinant multi-epitope antigen DIPOL in IgG-ELISA in a clinically defined cohort of CE patients. The serum samples from 149 CE patients were collected just before surgical or Percutaneous- Aspiration- Injection- Reaspiration (PAIR) procedures. Additionally, serum samples of patients with other parasitic infections (n=49) and healthy individuals (n=21) were also included in the study as controls. To investigate the association between the genotype of the parasite and DIPOL, cyst materials from 20 CE patients were sequenced. In terms of overall sensitivity, HF was higher than DIPOL (82.55%,78.52%, respectively). However, while the sensitivity of HF was higher than DIPOL in patients with active and transitional cysts (83.3%, 75.4%, respectively), sensitivity of DIPOL in inactive cysts was higher compared to HF (95.6%, 78.3%, respectively). The sensitivity of DIPOL depending on cyst stage was statistically significant (P= 0.041). In terms of specificity, DIPOL was found to be better than HF (97.71%, 91.43%, respectively). By genotyping, the majority of 20 patients showed G1 genotype (80%). All patients harboring G3 and G1/G3 cyst genotypes were positive with both antigens, while 87.5% of patients with G1 genotype were seropositive with HF and 75% with DIPOL. The overall sensitivity and high specificity of DIPOL suggest that this recombinant protein containing immunodominant epitopes is a potential substitute for the HF by serological tests for the diagnosis of CE., This study was produced from Eylem Akdur Ozturk’s doctoral thesis and supported by Teaching Staff Training Program. The study AC, MSL, RMR and CSO were also supported by the European Commission Seventh Framework Programme (FP7) under the HERACLES project (grant agreement 602051; http://www.heracles-fp7.eu/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, Peer reviewed